Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Colleague Insights
Living Resources
Conferences
Nursing Perspectives
Video Expert Opinion
Sign in
Join now
Published in Metastatic Breast Cancer

Journal Scan / Research · October 03, 2016

No Added Benefit of AZD8931 in Combination With Endocrine Therapy in Advanced Breast Cancer

Breast Cancer Research and Treatment

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Reshma Mahtani DO

Breast Cancer Research and Treatment
Inhibition of EGFR, HER2, and HER3 Signaling With AZD8931 in Combination With Anastrozole as an Anticancer Approach: Phase II Randomized Study in Women With Endocrine-Therapy-Naïve Advanced Breast Cancer
Breast Cancer Res Treat 2016 Sep 21;[EPub Ahead of Print], S Johnston, M Basik, R Hegg, W Lausoontornsiri, L Grzeda, M Clemons, L Dreosti, H Mann, M Stuart, M Cristofanilli

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated